Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 16, 2014Endocrine JournalOpen Access

Ameliorated pancreatic cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMitsuyoshi TakaharaThe University of OsakaTSToshihiko ShiraiwaOsaka City UniversityTMTaka‐aki MatsuokaWakayama Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Takahara et al. (2014) studied this question.

synapsesocial.com/papers/69d9ae102a25b240b7a3d730https://doi.org/10.1507/endocrj.ej14-0335
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes2004 · 427 citations
  2. 2Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications2009 · 637 citations
  3. 3Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patients2003 · 170 citations
  4. 4The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone2009 · 417 citations
  5. 5Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes2005 · 362 citations